Updated:
MediciNova
MediciNova advances Japanese-sourced clinical compounds through US regulatory pathways, with two Phase III-ready candidates targeting rare diseases.
MediciNova
MediciNova was incorporated in 2000 by co-founders Yuichi Iwaki and Kazuko Matsuda, with a cross-border structure anchored in La Jolla, California, and Tokyo, Japan. The firm went public on the Nasdaq in 2005 and later listed on the Jasdaq market in Japan, giving it access to both US and Japanese capital markets. Iwaki, previously an assistant professor at USC's Keck School of Medicine, built the company to bridge Japanese pharmaceutical discovery with US clinical development infrastructure. The firm acquires late-stage clinical assets, primarily from Japanese pharmaceutical companies, and funds their advancement through US and global regulatory pathways. Its lead candidate, MN-166 (ibudilast), has been studied in amyotrophic lateral sclerosis, progressive multiple sclerosis, and substance-use disorders. A second asset, MN-001 (tipelukast), targets idiopathic pulmonary fibrosis and nonalcoholic steatohepatitis (per the firm's official communications, 2024). The portfolio also contains MN-221 (bedoradrine) for acute asthma exacerbations and earlier-stage preclinical programs. MediciNova does not operate discovery labs — it licenses compounds that already carry phase II data from partners including Kyorin Pharmaceutical. As of December 2024, the firm held $44.7 million in cash and investments, funding operations without relying on partnership-dependent milestone payments (per its SEC filings, year-end 2024). The company maintains a lean, academic-affiliated team with its principal office in La Jolla and a subsidiary in Tokyo. In May 2024, MediciNova announced that a Department of Defense-funded trial evaluating MN-166 for Gulf War Illness would continue following a positive futility analysis (per the firm, May 2024). MediciNova's structure as a public biotech without a controlling pharmaceutical partner or founder-family owner creates an unusual governance dynamic — executive compensation and equity dilution sit alongside clinical milestones as allocator considerations. The dual-listing on Nasdaq and Jasdaq provides two liquidity venues, while the Japanese-sourced pipeline distinguishes it from domestically focused rare-disease peers.
General information
Firm type
Asset Manager
Year founded
2000
AUM
Undisclosed
Location
Region
North America
Country
United States
City
La Jolla
Corporate office
La Jolla, CA, United States
Additional offices
Tokyo, Japan
Principals
Yuichi Iwaki
President and Chief Executive Officer
Sector focus
Frequently asked questions
What is MediciNova's lead clinical asset, and what indications does it target?
MN-166 (ibudilast) is MediciNova's lead compound, an oral small-molecule phosphodiesterase and macrophage migration inhibitory factor inhibitor. The firm has studied it in ALS, progressive multiple sclerosis, substance-use disorders, and Gulf War Illness. A US Department of Defense-funded phase IIb trial in Gulf War Illness passed a futility analysis in May 2024 per the firm.
How does MediciNova source its drug candidates?
MediciNova licenses clinical-stage assets from Japanese pharmaceutical companies, notably Kyorin Pharmaceutical, avoiding in-house discovery. The model relies on acquiring compounds that have already demonstrated phase II safety and efficacy data in Japan, then advancing them through US and global regulatory filings.
Is MediciNova's financial runway sufficient to reach its next clinical milestones?
As of December 2024, MediciNova reported $44.7 million in cash and investments on its balance sheet. The company operates a lean cost structure and benefits from non-dilutive funding sources including a Department of Defense grant for the Gulf War Illness trial, though it remains a pre-revenue biotech with ongoing burn.
What is MN-001 (tipelukast), and where does it stand in development?
MN-001 is an oral leukotriene receptor antagonist and phosphodiesterase inhibitor in late-stage development for idiopathic pulmonary fibrosis and NASH. It has completed phase II/III trials in IPF in Japan and has received fast-track designation in the US.
Why is MediciNova listed on both Nasdaq and the Tokyo Stock Exchange's Jasdaq market?
The dual-listing mirrors the firm's cross-border structure: corporate headquarters in La Jolla, California, and a subsidiary in Tokyo. It provides access to both US and Japanese investors, and reflects the Japanese origin of its licensed drug portfolio.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: